2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-132830
    Sebetralstat 1933514-13-6 99.58%
    Sebetralstat (KVD900) is a plasma kallikrein inhibitor (WO2016083820). Sebetralstat can be used for the research of metabolic diseases.
    Sebetralstat
  • HY-145694
    CDK5-IN-3 2639542-32-6 99.49%
    CDK5-IN-3 (compound 11) is a potent and selective CDK5 inhibitor, with IC50s of 0.6 nM and 18 nM for CDK5/p25 and CDK2/CycA, respectively. CDK5-IN-3 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD).
    CDK5-IN-3
  • HY-15259A
    CP-640186 hydrochloride 591778-70-0 99.90%
    CP-640186 hydrochloride is an orally active and cell-permeable Acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. Acetyl-CoA carboxylase (ACC) is a key enzyme of fatty acid metabolism that enables the synthesis of malonyl-CoA. CP-640186 hydrochloride can also stimulate muscle fatty acid oxidation.
    CP-640186 hydrochloride
  • HY-P99194
    Evinacumab 1446419-85-7 99.24%
    Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia.
    Evinacumab
  • HY-P99211
    Otelixizumab 881191-44-2 99.64%
    Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes.
    Otelixizumab
  • HY-N0215S1
    L-Phenylalanine-d8 17942-32-4 99.62%
    L-Phenylalanine-d8 is the deuterium labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].
    L-Phenylalanine-d8
  • HY-13332
    Calcifediol-d6 78782-98-6 98.91%
    Calcifediol-d6 is the deuterium labeled Calcifediol. Calcifediol, a major circulating metabolite of vitamin D3, is a potent VDR ligand.
    Calcifediol-d6
  • HY-15565
    APD668 832714-46-2
    APD668 is a potent, selective and orally active agonist of G-protein coupled receptor GPR119, with EC50s of 2.7 nM and 33 nM for hGPR119 and rGPR119, respectively. APD668 shows no significant inhibition of any of the five major CYP isoforms with the exception of CYP2C9 (Ki=0.1 μM). APD668 can be used for the research of steatohepatitis and diabetes.
    APD668
  • HY-19480
    Ulodesine 548486-59-5 ≥99.0%
    Ulodesine is a purine nucleoside phosphorylase (PNP) inhibitor. Ulodesine inhibits PNP with IC50 value of 2.293 nM/L. Ulodesine can be used for the research of hyporucicemia.
    Ulodesine
  • HY-19870
    Setmelanotide 920014-72-8 99.93%
    Setmelanotide (RM-493) is a selective melanocortin 4 receptor (MC4R) agonist with EC50s of 0.27 nM and 0.28 nM for human and rat MC4R, respectively.
    Setmelanotide
  • HY-40136
    cis-4-Hydroxy-L-proline 618-27-9 ≥98.0%
    cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension.
    cis-4-Hydroxy-L-proline
  • HY-43470
    3α,12β-Dihydroxycholanoic acid 570-62-7
    3α,12β-Dihydroxycholanoic acid is a bile acid that can be isolated from urine specimens of healthy humans.
    3α,12β-Dihydroxycholanoic acid
  • HY-44170
    Pantothenate kinase-IN-2 902614-04-4 ≥98.0%
    Pantothenate kinase-IN-2 is a potent Pantothenate kinase 1/3 (PanK1/3) inhibitor with an IC50 of 0.14 μM and 0.36 μM. Pantothenate kinase-IN-2 is a promising agent for PKAN (PanK-associated neurodegeneration) and diabetes research.
    Pantothenate kinase-IN-2
  • HY-A0033
    Darifenacin 133099-04-4 99.81%
    Darifenacin (UK-88525) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin inhibits tumor growth in colorectal cancer cells and has anti-tumor effects.
    Darifenacin
  • HY-B0986
    Hexylresorcinol 136-77-6 99.52%
    Hexylresorcinol (4-Hexylresorcinol) is a natural compound found in plants with antimicrobial, anthelmintic, antiseptic and antitumor activities. Hexylresorcinol can induce apoptosis in squamous carcinoma cells. Hexylresorcinol is a reversible and noncompetitive inhibitor of α-glucosidase. Hexylresorcinol has protective effects against oxidative DNA damage.
    Hexylresorcinol
  • HY-B1730
    Phensuximide 86-34-0 99.35%
    Phensuximide is an orally active succinimide antiepileptic and anticonvulsant agent. Phensuximide inhibits cyclic AMP and cyclic GMP accumulation in depolarized brain tissue. Phensuximide can be used for the study of seizure and petit mal.
    Phensuximide
  • HY-N0538
    Xylitol 87-99-0 ≥98.0%
    Xylitol can be classified as a polyol and sugar alcohol, exhibiting inhibitory activity on cancer cell proliferation. It induces autophagy (Autophagy) and cell death in A549 cells by activating the autophagy signaling pathway, as evidenced by the increased expression of LC3-II and Atg5-Atg12 upon Xylitol treatment. Additionally, Xylitol inhibits acetaldehyde production by Candida species, thereby reducing their carcinogenic potential. In vivo, Xylitol induces alterations in the gut microbiota of mice, which may enhance cholesterol accumulation and upregulate hepatic ChREBP, while also slowing tumor growth in the B16F10 melanoma C57BL/6 mouse model.
    Xylitol
  • HY-N0628
    Kaempferitrin 482-38-2 99.94%
    Kaempferitrin is a natural flavonoid, possesses antinociceptive, anti-inflammatory, anti-diabetic, antitumoral and chemopreventive effects, and activates insulin signaling pathway.
    Kaempferitrin
  • HY-N1499
    Nystose 13133-07-8 ≥98.0%
    Nystose is a tetrasaccharide with two fructose molecules linked via beta (1→2) bonds to the fructosyl moiety of sucrose. Nystose exhibits prebiotic, immunomodulatory, and metabolism regulating activities. Nystose promotes the bone mineralization by activating the Wnt/β-catenin signaling pathway.
    Nystose
  • HY-N3021
    D-chiro-Inositol 643-12-9 ≥98.0%
    D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome.
    D-chiro-Inositol
Cat. No. Product Name / Synonyms Application Reactivity